Guja C, et al. - In this multicentre, double-blind study, the researchers compared the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin. They randomized (1:1) patients with persistent hyperglycaemia after an 8-week titration phase (glycated haemoglobin [HbA1c] 7.0%-10.5% [53-91 mmol/mol]) to exenatide QW or placebo. HbA1c change from baseline to week 28 was the primary endpoint. Body weight, 2-hour postprandial glucose, and mean daily IG dose was the included secondary endpoints. Data reported that exenatide QW significantly improved glucose control and reduced body weight, without increased hypoglycaemia or unexpected safety findings among patients with inadequate glycaemic control.